

Ron S. Israeli, et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 2

REMARKS

Claims 128 to 163 are pending in the subject application. Applicants have herein amended claims 161 and 162. These amendments are shown with the use of brackets and underlining in Attachment A hereto. The amendments to claims 161 and 162 are completely supported by the application as filed and thus raise no issue of new matter. Claims 145 through 160 and claim 163 have been canceled hereinabove without disclaimer or prejudice to applicants' right to pursue the subject matter of any or all of these claims in a continuation application.

Claims 128-144 and 161-162, as amended, are now pending in the application and await the Examiner's review and consideration. It is Applicants' understanding that pursuant to the filing of this Supplemental Amendment, the time for the Office to act on this application will be reset for a period of two (2) months from the Supplemental Amendment filing date.

Claims 145-163 embrace subject matter which is also claimed in U.S. Patent No. 6,150,508 to Murphy et al. issued November 21, 2000. As required by 35 U.S.C. §135(b), claims to this subject matter (numbered 145-162) were presented in a Supplemental Amendment filed November 21, 2001, i.e., not more than one year after the issue date of the U.S. Patent No. 6,150,508. Claim 163, was submitted in a further Supplemental Amendment filed February 6, 2002.

Applicants believe that the cancellation of claims 145-160, and

N


Ron S. Israeli, et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 3

claim 163 (without disclaimer or prejudice) and the amendment of claims 161-162 assists in reducing, and therefore clarifying the issues relating to the interfering subject matter recited in the present claims in view of that which is claimed in Murphy et al., U.S. Patent No. 6,150,508, and that which is claimed in Bander, U.S. Patent No. 6,107,090. Cancellation of claims 145-160 and 163 will therefore result in simplifying the Examiner's analysis of the issues relating to the proposed interference.

It a telephone interview would be of assistance in advancing the prosecution of the application, or if applicants' understanding of the time for Patent Office action on this case as described above is not correct, applicants' undersigned attorney respectfully invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,


John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

N

Ron S. Israeli, et al.
Serial No.: 08/470,735
Filed: June 6, 1995
Page 4

ATTACHMENT A

Amended Claims

--161. (amended) A monoclonal antibody having an antigen-binding region specific for the extracellular domain of [prostatic] prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.--

--162. (amended) A monoclonal antibody having an antigen-binding region specific for the outer membrane domain of [prostatic] prostate specific membrane antigen, the amino acid sequence of which antigen is set forth in SEQ ID NO:2.--

N